Nuo Therapeutics, Inc. Overview
Pro stress-test →Nuo Therapeutics is a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds. In Q1 2026, total revenues reached approximately $1.3 million, increasing 169% over the prior-year first quarter, with Aurix branded product revenues up over 30% sequentially.
Strategic Profile
Pro stress-test →Nuo is leveraging Aurix adoption and a Smith+Nephew private-label distribution agreement to drive revenue growth. The market is responding favorably to continued improvement in Medicare-related reimbursement for Aurix and a vastly changed overall reimbursement landscape. However, the company remains pre-profitability with significant financial constraints and ongoing dependence on debt financing to fund growth.
Competitive Landscape
Pro stress-test →Nuo's Aurix System competes in the autologous PRP therapy market for chronic wound care. Direct competitors include other regenerative medicine and wound care solution providers, though Nuo's point-of-care PRP generation model differentiates it. The improving Medicare reimbursement environment is reducing barriers to adoption, but Nuo remains early-stage relative to larger, well-capitalized wound care competitors with established distribution networks.
Industry Context
Nuo Therapeutics, Inc. operates in Regenerative medicine and chronic wound care.
Key facts
Headquarters: Houston, TX · Revenue: $3.31M TTM · Market cap: $60.7M